Frontage (01521) completes the acquisition of Shanghai Guanhe Medical Technology Co., Ltd.

date
18:29 03/03/2026
avatar
GMT Eight
Fangda Holdings (01521) announced that its wholly-owned subsidiary, Fangda Shanghai, intends to acquire Shanghai Guanhe Pharmaceutical Technology Co., Ltd. (the Target Company) for 2.7 billion yuan. All the conditions precedent specified in the share transfer agreement have been fulfilled, and in accordance with the terms and conditions of the agreement, delivery was completed on March 3, 2026. Following the completion of the transaction, the Target Company has become a wholly-owned subsidiary of the Company, and the financial performance of the Target Company and its subsidiaries will be consolidated into the financial statements of the Group.
FRONTAGE (01521) announced that its wholly-owned subsidiary, Fangda Shanghai, plans to acquire Shanghai Guanhe Medical Technology Co., Ltd. (the Target Company) for a total of 270 million yuan. All preconditions set out in the share transfer agreement have been met, and according to the terms and conditions of the agreement, the completion took place on March 3, 2026. Following the completion, the Target Company has become a wholly-owned subsidiary of the company, and the financial performance of the Target Company and its subsidiaries will be consolidated into the group's financial statements.